Background: To analyze the clinical features, outcomes including efficacy of treatment, and prognostic factors of patients with immunoglobulin D multiple myeloma (IgD MM).
as immunomodulatory agents and proteasome inhibitors, have shown effectiveness against the disease. In addition, advances in supportive care and the development of bone-targeting agents may contribute to improved outcomes. These developments may have led to changes in the clinical course and outcomes of IgD MM.
Little is known regarding the effectiveness of autologous stem cell transplantation (SCT) or the effects of new drugs in patients with IgD MM. Most studies have been small case series, lacking complete data on individual patients and yielding contradictory results. For example, one study reported that overall survival (OS) time in patients undergoing autologous SCT was >60 months, suggesting that autologous SCT improved outcomes in patients with IgD MM [5] . A second study, however, found that survival after autologous SCT was only 12 months, with IgD isotype being an independent prognostic factor for poor survival after autologous SCT [6] . Several studies have suggested that IgD MM is highly sensitive to novel therapeutic agents such as bortezomib and thalidomide [7, 8] .
A number of clinical and laboratory variables have been identified as prognostic factors in patients with MM. The International Staging System (ISS), based on the serum concentrations of b 2 microglobulin and albumin, is considered the most extensive and validated prognostic staging system for patients with this disease [9] . In addition, certain cytogenetic and molecular features have emerged as key prognostic determinants [10, 11] . Although prognostic factors in IgD MM may be distinct owing to the unique clinical features of this disease isotype, they have not yet been identified. For example, light chain subtype and white blood cell count have been suggested as prognostic indicators in IgD MM, but they were not validated and were limited due to the high frequency of lambda light chain type in IgD MM [2] .
Since 2005, the Korean Multiple Myeloma Working Party (KMMWP) has registered all MM patients throughout Korea using a web-based database system, the 'Korean Myeloma Registry' (KMR). Recently, we published a survival analysis on the total of 3209 patients in this registry [12] . We found that IgD MM was associated with shorter OS than other MM isotypes but that isotype per se was not an independent prognostic factor for survival. We therefore further analyzed the clinical features, outcomes, and prognostic factors of IgD MM patients using data from the KMR. In addition, we assessed the roles of SCT and new drugs in the treatment of IgD MM.
design and methods
We identified 77 IgD MM patients treated in 19 institutions throughout Korea between 1997 and 2009. Records of these patients were reviewed using the KMR database (www.myeloma.or.kr). Each institution was requested to complete missing data using additional case report forms on. Patients who had overt MM based on International Myeloma Working Group (IMWG) diagnostic criteria were selected. Thus, two patients were excluded because they were diagnosed with single or multiple plasmacytoma [13] .
definition of response
Response was assessed using immunofixation-based European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry (EBMT/IBMTR) criteria [14] . Complete response (CR) included negative immunofixation of serum and urine. With the limitation of retrospective analysis, this also included patients in whom electrophoresis is negative but in whom immunofixation is positive. Partial response (PR) was defined as a ‡50% decrease in serum M-protein concentration or, in patients lacking serum M-protein measurements, a ‡90% decrease in urine M-protein excretion. . Hypercalcemia (serum calcium concentration ‡12 mg/dl) and renal function impairment (serum creatinine concentration ‡2 mg/dl) were present in 20 (27%) and 40 (53%) patients, respectively. Forty-eight patients (64%) were of stage III by the ISS and 92% were of stage III by the Durie-Salmon Staging System (DSS). The main presenting features were bone pain (77%) and fatigue (77%). At diagnosis, 21 patients (28%) had urinary symptoms such as polyuria or nocturia. Five patients (7%) had hepatosplenomegaly or lymphadenopathy. Median serum creatinine concentration was 2.3 mg/dl (range, 0.6-13.9 mg/dl) and median serum b 2 microglobulin concentration was 8.0 mg/dl (range, 1.5-103 mg/dl). Median serum M-protein concentration was 1.4 g/dl and urine M-protein concentration was 1.1 g/dl. Forty-nine patients were assessable for chromosomal analysis, 46 by conventional cytogenetics, and 3 by FISH analysis (Table 2 ). Of these, 26 patients (53%) had chromosomal abnormalities, with 19 (39%) showing complex chromosomal abnormalities and 12 (25%) demonstrating hypoploidy or deletion of chromosome 13 [del (13) ].
statistical analysis

reatment response and survival
Three patients did not receive chemotherapy because of poor performance or patient refusal. Thirty-nine patients (54%) were treated with VAD (vincristine, adriamycin, and dexamethasone); the 37 patients assessable for response had an objective response rate of 56%. Four patients (10%) showed Figure 1A ). Median survival time after treatment failure of first-line chemotherapy was 8.8 months (95% CI 4.3-13.4 months). Univariate analysis showed that, among pretreatment parameters, age, performance status, extramedullary plasmacytoma, percentage of plasma cells in bone marrow, platelet count, serum creatinine level, serum b 2 microglobulin concentration, and ISS stage were significantly associated with OS (Table S1 , available at Annals of Oncology online). Multivariate analysis showed that age £65 years (versus >65 years), absence (versus presence) of extramedullary plasmacytoma, absence (versus presence) of del (13) or hypoploidy, serum b 2 microglobulin level <8.0 mg/dl (versus ‡8.0 mg/dl), and platelet count ‡100 000/mm 3 (versus <100 000/mm 3 ) were significant predictors of longer OS (Table 3) . Median OS of patients responsive to first-line treatment was 28.6 months, significantly longer than that of patients with unresponsive disease (13.3 months, P = 0.004) ( Figure 1B) . [12] . In addition to the aggressive clinical features of IgD MM, poor survival of these patients may be associated with problems related to delayed diagnosis [15, 16] . Patients with renal failure of unknown cause, bone pain, small serum Mprotein bands, or undefined Ig isotype should be suspected of having IgD MM. The reasons underlying the distinct clinical features of IgD MM have yet to be determined, but the unique biological behavior of IgD MM is expected to be a determining factor. However, the underlying tumor biology responsible for the differences between IgD MM and other MM isotypes remains to be defined. The findings presented here illustrate previously undescribed aspects of IgD MM. We observed a high frequency of initial chromosomal abnormalities in patients with IgD MM. Although conventional cytogenetics analysis has previously revealed abnormal karyotypes in 33% of patients with MM [17] , we found that 53% of patients with IgD MM had chromosomal abnormalities. In combination with the high frequency of end organ damage, the increased proportion of cytogenetic abnormalities in such patients may contribute to poor prognosis. We found that the factors prognostic for reduced OS in patients with IgD MM were advanced age, the presence of cytogenetic abnormalities such as del (13) or hypoploidy, extramedullary plasmacytoma, and high serum b 2 microglobulin concentration, all of which have previously been reported to be prognostic factors in patients with MM. In our previous study using registry data on 3029 MM patients, we found that age >65 years, poor performance status, platelet count <100 000/mm 3 , serum albumin <3.5 g/dl, serum creatinine ‡2.0 mg/dl, serum b 2 microglobulin ‡3.5 mg/dl, the presence of extramedullary plasmacytoma, and chromosomal abnormalities were all independent prognostic factors for reduced OS [12] . Our finding of similar prognostic factors in patients with IgD MM suggests that IgD MM should be considered a rare subgroup of MM with aggressive features rather than a single parameter of poor prognosis. Owing to the low frequency of IgD MM, it may be more reasonable to consider prognostic factors such as cytogenetic data or serum b 2 microglobulin level, rather than IgD isotype, as predictive of overall patient outcomes. In contrast, ISS score was not of prognostic significance in patients with IgD MM. Stage III ISS patients may be a composite group, comprising patients with increased serum b 2 microglobulin level owing to tumor burden and poor clearance caused by renal failure [18] . As more than half of such patients had renal impairment, the prognostic importance of serum b 2 microglobulin may be weakened. When we dichotomized patients based on a median serum b 2 microglobulin concentration of 8.0 mg/dl, we found that serum b 2 microglobulin concentration could predict patient survival. In contrast, a risk stratification system for IgD MM [2] , based on light chain subtype and white blood cell count, was not predictive in our patient population (data not shown). A novel risk scoring system may be needed to stratify patient prognosis. Finally, the response rate to first-line chemotherapy regimens containing one of the new drugs such as bortezomib or thalidomide was 81%, compared with a response rate to VAD of 56%. Generally, the VAD regimen results in a 55%-65% response rate in newly diagnosed myeloma patients [19] . Although the response rates of IgD MM patients to VAD and to regimens containing new drugs were similar to the response rates of patients with other myeloma isotypes, OS was poor in patients with IgD MM. Despite initial favorable responses, salvage treatment was ineffective and survival after relapse was particularly poor at only 9 months. In contrast, we found that OS was significantly longer in patients who achieved PR or CR to first-line chemotherapy. Younger patients who received upfront ASCT showed moderately improved survival, especially patients with chemoresponsive disease, with longer survival than that observed with conventional chemotherapy. New drugs such as bortezomib and the immune-modulating drugs, as well as ASCT, may improve the outcomes of patients with IgD MM. New treatment strategies that aim to induce high-quality responses before ASCT and maintain the response after ASCT may be needed to improve the outcomes of such patients.
outcomes of patients who received SCT
We found that the OS of our patients was shorter than in previous studies conducted over the past 10 years. This discrepancy may be because patients with advanced disease were more common in our population; our study was multi-institutional and we excluded patients who did not meet the IMWG criteria for MM; previous studies excluded from survival analysis patients who did not receive chemotherapy or who experienced early death after chemotherapy [3, 5, 16] .
Patients with IgD MM showed smaller monoclonal protein bands, findings consistent with reported previously [1] [2] [3] . We found that 89% of IgD MM patients had lambda light chain and that these patients had poorer outcomes than those with kappa light chains. The dominant light chain type in IgD MM and the association between light chain type and prognosis in IgD MM patients have been inconsistent across studies. For example, several studies have reported that 80%-94% of patients with IgD MM had lambda light chains and this was associated with poorer outcomes, whereas one study reported a kappa/lambda ratio close to 1 and similar survival in the two subgroups [1] [2] [3] . In addition, we found that the frequency of extramedullary plasmacytoma at presentation was relatively low, although this finding has also been inconsistent across studies. These differences may be due to selection biases and the limitations of retrospective studies, indicating a need for prospective cohort studies.
In conclusion, we found that the clinical features and prognosis of patients with IgD MM differed from of those of patients with other immunoglobulin MM subtypes. The underlying tumor biology responsible for these differences remains to be determined. The use of intensive treatment strategies before and after SCT may improve outcomes in younger patients. references
